Cargando…

A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma

Survivin is a microtubule-associated protein believed to be involved in preserving cell viability and regulating tumor cell mitosis, and it is overexpressed in many primary tumor types, including melanoma. YM155 is a first-in-class survivin suppressant. The purpose of this Phase 2 study was to evalu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kudchadkar, Ragini, Ernst, Scott, Chmielowski, Bartosz, Redman, Bruce G, Steinberg, Joyce, Keating, Anne, Jie, Fei, Chen, Caroline, Gonzalez, Rene, Weber, Jeffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430257/ https://www.ncbi.nlm.nih.gov/pubmed/25533314 http://dx.doi.org/10.1002/cam4.363

Ejemplares similares

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1
por: Wagner, Verena, et al.
Publicado: (2014)

Population pharmacokinetic modeling of Sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma
por: Aoyama, Yumiko, et al.
Publicado: (2012)

Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells
por: Gholizadeh, Shima, et al.
Publicado: (2018)

Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve Suppression of mTORC1 by AMPK
por: Danielpour, David, et al.
Publicado: (2019)

Author Correction: Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve Suppression of mTORC1 by AMPK
por: Danielpour, David, et al.
Publicado: (2019)

Emerging Effects of Sepantronium Bromide (YM155) on MOLT-4 Cell Line Apoptosis Induction and Expression of Critical Genes Involved in Apoptotic Pathways
por: Shojaei Moghadam, Kobra, et al.
Publicado: (2020)

Adaptation to chronic exposure to sepantronium bromide (YM155), a prototypical survivin suppressant is due to persistent DNA damage-response in breast cancer cells
por: Wani, Tasaduq H., et al.
Publicado: (2018)

Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment
por: Aoyama, Yumiko, et al.
Publicado: (2012)

Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer
por: Clemens, Michael R., et al.
Publicado: (2014)

Effect of Sepatronium Bromide (YM-155) on DNA Double-Strand Breaks Repair in Cancer Cells
por: Majera, Dusana, et al.
Publicado: (2020)

The cost of unresectable stage III or stage IV melanoma in Italy
por: Maio, Michele, et al.
Publicado: (2012)

YM155 Induces EGFR Suppression in Pancreatic Cancer Cells
por: Na, Young-Soon, et al.
Publicado: (2012)

Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension
por: Blanco, Isabel, et al.
Publicado: (2023)

YM155 enhances the cytotoxic activity of etoposide against canine osteosarcoma cells
por: ONG, Siew Mei, et al.
Publicado: (2019)

Epigenetic Changes at the Birc5 Promoter Induced by YM155 in Synovial Sarcoma
por: Mika, Aleksander, et al.
Publicado: (2019)

YM155 Inhibits NleB and SseK Arginine Glycosyltransferase Activity
por: Zhu, Congrui, et al.
Publicado: (2021)

The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma
por: Xia, Hongping, et al.
Publicado: (2015)

Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance
por: Voges, Yvonne, et al.
Publicado: (2016)

Advantages of ypTNM Staging in Post-surgical Prognosis for Initially Unresectable or Stage IV Gastric Cancers
por: Jeong, Gyu-Seong, et al.
Publicado: (2020)

Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter
por: Radic-Sarikas, Branka, et al.
Publicado: (2017)

Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment
por: Vay, Christian, et al.
Publicado: (2021)

Paradigm Shift in the Treatment of Elderly Patients With Unresectable Stage IV Colorectal Cancer
por: Kim, Nam Kyu
Publicado: (2014)

The Role of Surgery for Asymptomatic Primary Tumors in Unresectable Stage IV Colorectal Cancer
por: Kim, Young Wan, et al.
Publicado: (2013)

Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy
por: Blankenstein, Stephanie A., et al.
Publicado: (2020)

Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells
por: Tao, Yan-Fang, et al.
Publicado: (2012)

YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway
por: Chang, Bill H, et al.
Publicado: (2015)

Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels
por: Sim, Mei Yi, et al.
Publicado: (2017)

Dioxonaphthoimidazoliums AB1 and YM155 disrupt phosphorylation of p50 in the NF-κB pathway
por: Ho, Si Han Sherman, et al.
Publicado: (2016)

Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines
por: Michaelis, Martin, et al.
Publicado: (2020)

Primary tumor resection in stage IV unresectable colorectal cancer: what has changed?
por: Pędziwiatr, Michał, et al.
Publicado: (2017)

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs
por: Iwasa, T, et al.
Publicado: (2010)

Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin
por: Nakamura, Naoto, et al.
Publicado: (2012)

Survivin inhibitor YM155 suppresses gastric cancer xenograft growth in mice without affecting normal tissues
por: Cheng, Xiao Jiao, et al.
Publicado: (2016)

YM155 decreases radiation-induced invasion and reverses epithelial–mesenchymal transition by targeting STAT3 in glioblastoma
por: Zhang, Xin, et al.
Publicado: (2018)

Structure-Activity Relationship Analysis of YM155 for Inducing Selective Cell Death of Human Pluripotent Stem Cells
por: Go, Young-Hyun, et al.
Publicado: (2019)

YM155 sensitizes HeLa cells to TRAIL-mediated apoptosis via cFLIP and survivin downregulation
por: Chandrasekaran, Arun Pandian, et al.
Publicado: (2020)

Outcomes of patients with unresected stage III and stage IV non-small cell lung cancer: A single institution experience
por: Tiwana, Manpreet Singh, et al.
Publicado: (2013)

Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma
por: Eroglu, Zeynep, et al.
Publicado: (2011)

YM155 potently triggers cell death in breast cancer cells through an autophagy-NF-kB network
por: Véquaud, Eloïse, et al.
Publicado: (2015)

Correction to: YM155 decreases radiation-induced invasion and reverses epithelial–mesenchymal transition by targeting STAT3 in glioblastoma
por: Zhang, Xin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8qgrqgmpkqmb0o247a206l7iao